Exploring the Impact of Fatty Acids on Ovarian Cancer Progression
DOI:
https://doi.org/10.47611/jsrhs.v13i3.6951Keywords:
Lipid droplets, ovarian cancer, metastasis, fatty acidsAbstract
Ovarian cancer (OC) stands as a formidable challenge in women's health, constituting a significant portion of gynecological-related deaths. The aggressive nature of epithelial ovarian cancer (EOC) manifests as a major hindrance to effective treatment. This study delves into the complex interplay between fatty acid stimuli, cellular signaling pathways, and subsequent cellular responses in the context of ovarian cancer, employing mouse ovarian cancer cell lines ID8 with distinct genetic backgrounds—those harboring BRCA2/p53 mutations and those with solely p53 mutations. Despite the well-established role of fatty acids in cancer cell growth, invasion, and metastasis, the intricate dynamics of how these molecules modulate signaling pathways and influence cellular outcomes, particularly in ovarian cancer with specific genetic mutations, remain less explored. In this context, the study aims to elucidate the differential responses observed in cell signaling activation and cell proliferation, shedding light on the unique sensitivity of ID8 cells with both p53 and BRCA2 mutations to odd chain fatty acids. Additionally, the investigation underscores the correlation between fatty acid types and lipid accumulation, offering valuable insights into the potential mechanisms driving ovarian cancer aggressiveness. These findings emphasize the importance of considering genetic backgrounds in tailoring therapeutic strategies, paving the way for more effective and personalized approaches in the treatment of ovarian cancer.
Downloads
References or Bibliography
Bankhead, C.R., Collins, C., Stokes-Lampard, H., Rose, P., Wilson, S., Clements, A., Mant, D., Kehoe, S.T., and Austoker, J. (2008). Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG 115, 1008-1014.
Chaudhry, S., Thomas, S.N., and Simmons, G.E., Jr. (2022). Targeting lipid metabolism in the treatment of ovarian cancer. Oncotarget 13, 768-783.
Coleridge, S.L., Bryant, A., Kehoe, S., and Morrison, J. (2021). Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 2, CD005343.
Cortés-Guiral, D., Hübner, M., Alyami, M., Bhatt, A., Ceelen, W., Glehen, O., Lordick, F., Ramsay, R., Sgarbura, O., Van Der Speeten, K., et al. (2021). Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 7, 91.
Cummings, M., Nicolais, O., and Shahin, M. (2022). Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction. Diagnostics (Basel) 12.
Desai, A., Xu, J., Aysola, K., Qin, Y., Okoli, C., Hariprasad, R., Chinemerem, U., Gates, C., Reddy, A., Danner, O., et al. (2014). Epithelial ovarian cancer: An overview. World J Transl Med 3, 1-8.
Gaitskell, K., Hermon, C., Barnes, I., Pirie, K., Floud, S., Green, J., Beral, V., Reeves, G.K., and Collaborators, M.W.S. (2022). Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study. Cancer Epidemiol 76, 102074.
Guo, T., Dong, X., Xie, S., Zhang, L., Zeng, P., and Zhang, L. (2021). Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer. Cancer Manag Res 13, 3081-3100.
Khashaba, M., Fawzy, M., Abdel-Aziz, A., Eladawei, G., and Nagib, R. (2022). Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach. J Egypt Natl Canc Inst 34, 6.
Kim, D.H., Song, N.Y., and Yim, H. (2023). Targeting dysregulated lipid metabolism in the tumor microenvironment. Arch Pharm Res 46, 855-881.
Kobel, M., and Kang, E.Y. (2022). The Evolution of Ovarian Carcinoma Subclassification. Cancers (Basel) 14.
Koshiyama, M., Matsumura, N., and Konishi, I. (2014). Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int 2014, 934261.
Koundouros, N., and Poulogiannis, G. (2020). Reprogramming of fatty acid metabolism in cancer. Br J Cancer 122, 4-22.
Lheureux, S., Gourley, C., Vergote, I., and Oza, A.M. (2019). Epithelial ovarian cancer. Lancet 393, 1240-1253.
Li, Z., Fang, X., and Wang, S. (2023). Omentum provides a special cell microenvironment for ovarian cancer. Cancer Rep (Hoboken) 6, e1858.
Lim, H.J., and Ledger, W. (2016). Targeted therapy in ovarian cancer. Womens Health (Lond) 12, 363-378.
Mukherjee, A., Chiang, C.Y., Daifotis, H.A., Nieman, K.M., Fahrmann, J.F., Lastra, R.R., Romero, I.L., Fiehn, O., and Lengyel, E. (2020). Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. Cancer Res 80, 1748-1761.
Otsuka, I. (2021). Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations. Int J Mol Sci 22.
Qu, Q., Zeng, F., Liu, X., Wang, Q.J., and Deng, F. (2016). Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Dis 7, e2226.
Rickard, B.P., Conrad, C., Sorrin, A.J., Ruhi, M.K., Reader, J.C., Huang, S.A., Franco, W., Scarcelli, G., Polacheck, W.J., Roque, D.M., et al. (2021). Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response. Cancers (Basel) 13.
Schiliro, C., and Firestein, B.L. (2021). Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation. Cells 10.
Sun, Z., Jiang, Q., Li, J., and Guo, J. (2020). The potent roles of salt-inducible kinases (SIKs) in metabolic homeostasis and tumorigenesis. Signal Transduct Target Ther 5, 150.
Voronova, V., Vislobokova, A., Mutig, K., Samsonov, M., Peskov, K., Sekachev
a, M., Materenchuk, M., Bunyatyan, N., and Lebedeva, S. (2022). Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. Front Oncol 12, 1035884.
Zhao, G., Cardenas, H., and Matei, D. (2019). Ovarian Cancer-Why Lipids Matter. Cancers (Basel) 11.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Congyu Shi; Zhongchi Li

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.